Clinical Trials on Periodic Fever in Norway

Total 12 results

University of Bergen
Haukeland University Hospital

Completed

Postprandial Metabolism in Healthy Young Subjects (PoMet)

Biomarkers | Postprandial Period | Fasting

Norway
Novartis Pharmaceuticals

Completed

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients (B-Confident)

Cryopyrin-associated Periodic Syndromes (CAPS) | Familial Cold Autoinflam Syn (FCAS) | Muckle-wells Syn (MWS) | Neonatal Onset Multisystem Inflam Disease (NOMID)

Switzerland, United States, Germany, Norway, Austria
Molde University College

Completed

MST in Patients With Inflammatory Rheumatic Disease

Inflammatory Rheumatism

Norway
Molde University College

Completed

HIIT for Inflammatory Rheumatic Disease: Man vs Machine

Inflammatory Rheumatism

Norway
Helse Nord-Trøndelag HF
Haukeland University Hospital; Addis Ababa University

Recruiting

The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa (RHD-CaSS)

Rheumatic Heart Disease | Anticoagulant Adverse Reaction

Norway, Ethiopia
AstraZeneca

Completed

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

Perennial Allergic Rhinitis | Hay Fever

United States
Bavarian Nordic

Recruiting

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Chikungunya Virus Infection

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317

Chikungunya Virus

United States
AstraZeneca

Completed

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

Allergic Rhinitis | Perennial Allergic Rhinitis | Hay Fever

United States
AstraZeneca

Completed

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

Allergic Rhinitis | Perennial Allergic Rhinitis | Hay Fever

United States, Canada
Novartis Pharmaceuticals

Completed

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Malignant Melanoma

Canada, Italy, Czechia, Australia, France, Greece, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Slovakia, Slovenia, Japan, Turkey, Argentina, Finland, Norway, Brazil, Latvia, Lithuania, Poland, Portugal
AstraZeneca

Completed

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Seasonal Allergic Rhinitis | Hay Fever

United States

Clinical Trials on Periodic Fever in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations